Want to see DNLI full AI Analyst Report?
DNLI Stock Chart & Stats
$20.57
$0.28(1.32%)
At close: 4:00 PM EST
$20.57
$0.28(1.32%)
Day’s Range― - ―
52-Week Range$12.58 - $24.65
Previous CloseN/A
Volume399.31K
Average Volume (3M)1.86M
Market Cap
$3.70B
Enterprise Value$3.38B
Total Cash (Recent Filing)$987.68M
Total Debt (Recent Filing)$40.05M
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Jul 30, 2026EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.88
Shares Outstanding158,709,730
10 Day Avg. Volume2,058,342
30 Day Avg. Volume1,864,753
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)2.86
Price to Sales (P/S)0.00
P/FCF Ratio-6.86
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-591.93
Enterprise Value/Ebitda-6.85
Forecast
1Y Price Target
$34.33Price Target Upside66.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.43
Revenue Forecast (FY)$42.49M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet With Very Low LeverageVery low debt and substantial stockholders' equity (~$926.1M) provide durable solvency and optionality for a development-stage biotech. This financial buffer reduces immediate refinancing risk, supports multi-year R&D programs, and strengthens negotiating leverage with partners and licensors.
Non-dilutive Funding Via FDA Voucher MonetizationMonetizing a Rare Pediatric Disease Priority Review Voucher delivers a meaningful, non-dilutive cash infusion that materially extends runway. This structural funding reduces near-term capital needs, enabling continued investment in BBB-enabled programs without immediate equity dilution.
Proprietary BBB TransportVehicle PlatformA platform that reliably improves CNS delivery is a durable competitive advantage in neurology, allowing multiple modality programs (small molecules and biologics). It supports program diversification across Parkinson's, Alzheimer's and rare disorders and underpins long-term partnership and pipeline value.
Bears Say
High And Accelerating Cash BurnConsistently large negative operating and free cash flows indicate substantial ongoing funding requirements. Accelerating FCF deterioration (-68.1% YoY) creates a structural need for external financing or milestone receipts, increasing dilution risk or forcing reprioritization of R&D over the medium term.
No Recurring Product Revenue; Volatile Collaboration TimingThe absence of recurring product revenue makes financial performance dependent on lump-sum collaboration payments and milestone timing. This creates pronounced revenue cliffs and low visibility into sustainable cash flows, hampering long-term planning and heightening dependence on external financing or asset monetization.
Pipeline Concentration Risk After Phase 2b FailureA failed late-stage trial materially narrows near-term clinical catalysts and destroys expected value from a partnered program. This elevates R&D execution risk, pressures resource allocation, and may strain partner relations, leaving the company reliant on fewer programs to deliver long-term value.
Denali Therapeutics News
DNLI FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $12.58 and its highest was $24.65 in the past 12 months.
What is Denali Therapeutics’s market cap?
Denali Therapeutics’s market cap is $3.70B.
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is Jul 30, 2026 which is in 24 days.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on May 07, 2026. The company reported -$0.69 earnings per share for the quarter, beating the consensus estimate of -$0.723 by $0.033.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate is -0.71.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 158,709,730 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -$0.69 in its last earnings report, beating expectations of -$0.723. Following the earnings report the stock price went down -0.457%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Currently, no hedge funds are holding shares in DNLI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Denali Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.33 (66.91% Upside)
$34.33 (66.91% Upside)
Blogger Sentiment
Bullish
DNLI Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 27.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.35%
12-Months-Change
Fundamentals
Return on Equity
-52.20%
Trailing 12-Months
Asset Growth
-0.42%
Trailing 12-Months
Company Description
Denali Therapeutics
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
DNLI Stock 12 Month Forecast
Average Price Target
$34.33
▲(66.91% Upside)
Technical Analysis
Agios Pharma
―
Celcuity
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Ownership Overview
5.34% Insiders
24.13% Mutual Funds
40.65% Other Institutional Investors
12.41% Public Companies and
Individual Investors